Get the Stockscreener App
47.99
1.48%
-0.72
After Hours:
47.51
-0.48
-1.00%
Moderna Inc stock is traded at $47.99, with a volume of 11.26M.
It is down -1.48% in the last 24 hours and up +53.81% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$48.71
Open:
$49.475
24h Volume:
11.26M
Relative Volume:
0.95
Market Cap:
$18.75B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-5.4971
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+14.73%
1M Performance:
+53.81%
6M Performance:
+40.53%
1Y Performance:
+15.89%
1-Day Range:
$46.59
$49.48
1-Week Range:
$40.70
$55.20
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
47.99 | 19.03B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.84 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.65 | 79.20B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
833.16 | 50.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.35 | 47.29B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
337.79 | 37.55B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price - TechStock²
Behind the Scenes of Moderna's Latest Options Trends - Benzinga
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - ACCESS Newswire
Aug Momentum: Is Moderna Inc a momentum stockJuly 2025 Levels & Capital Protection Trading Alerts - baoquankhu1.vn
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - lansingstatejournal.com
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities - hattiesburgamerican.com
Hecla Mining, Moderna, And Micron Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio? - Benzinga
Aug PostEarnings: Is Moderna Inc a turnaround storyMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug PreEarnings: Will TriSalus Life Sciences Inc benefit from rate cutsJuly 2025 Movers & Reliable Intraday Trade Alerts - baoquankhu1.vn
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism (Video) - Social News XYZ
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk - TechStock²
Why Moderna (MRNA) Is Up 16.4% After Five-Year Data On Personalized Melanoma mRNA Therapy - Yahoo Finance
Moderna, Inc. $MRNA Shares Sold by Baillie Gifford & Co. - MarketBeat
Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism - Yahoo
Moderna Options Spot-On: On January 23rd, 191.29K Contracts Were Traded, With 974.59K Open Interest - 富途资讯
The Globe’s stars and dogs for the week - The Globe and Mail
Moderna's Growth Strategy Seen as Reassuring Investors -- Market Talk - 富途资讯
Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness - Intellectia AI
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap DownHere's What Happened - MarketBeat
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg - BioSpace
Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… - marketscreener.com
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - livingstondaily.com
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials - TechStock²
Intel, GE Aerospace, Moderna, Abbott, Mobileye, McCormick, and More Stock Movers - Barron's
Moderna (NASDAQ:MRNA) Trading Up 10.2%Time to Buy? - MarketBeat
Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally - FinancialContent
Moderna (MRNA) Halts Phase 3 Vaccine Development Amid U.S. Regulatory Challenges - GuruFocus
Moderna (MRNA) Sees Bullish Activity with Increased Options Trading - GuruFocus
Moderna cutting R&D on vaccines amid U.S. pushback: CEO (MRNA) - Seeking Alpha
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV - kfgo.com
Moderna-Merck mRNA Vaccine Slashes Melanoma Recurrence by 49% at 5 Years - WebProNews
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Intel, GE Aerospace, Moderna, Abbott, Arista, Mobileye, McCormick, and More Movers - Barron's
Moderna (MRNA) Stock Surge Boosts ETFs with High Exposure - GuruFocus
Moderna (MRNA) Surges Over 20% This Week, Hits 52-Week High - GuruFocus
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - Yahoo Finance
Moderna (MRNA) CEO Cites U.S. Vaccine Opposition as Barrier to New Trials - GuruFocus
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melano - pnj.com
Moderna is curbing investment in vaccine trials due to US backlash - bostonglobe.com
Moderna’s rally ripples through biotech and health care ETFs - Seeking Alpha
Moderna (MRNA) Shares Surge to New 52-Week High - GuruFocus
Moderna shares soar through the week, momentum data points toward caution - MSN
Moderna extends rally on positive cancer vaccine results - Sherwood News
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse - FinancialContent
Moderna Stock Explodes To New 52-Week High: What's Driving The Action? - Benzinga
Moderna shares soar through the week, momentum data points toward caution (MRNA:NASDAQ) - Seeking Alpha
Moderna pops 17%is there life in MRNA, down 90% from COVID high? - MSN
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
16.87%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):